Premier Fiscal Services Private Limited, a promoter group entity of Gennex Laboratories Limited , has pledged 25,00,000 equity shares to secure a business loan. The disclosure was submitted to BSE Limited on June 10, 2026, under Regulation 31(1) and (2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

The pledge was created in favor of Vidya Tradecon Private Limited on June 9, 2026. The transaction involves 25,00,000 shares, representing 1.029% of the total share capital of Gennex Laboratories Limited. The pledge is set to expire on December 7, 2026.

Details of the Encumbrance

The filing outlines the specifics of the pledge, including the purpose and the financial coverage. The shares were deposited with BMD Securities Limited, with a specific DP ID and Client ID assigned for the transaction.

Financials and Security Cover

The primary reason for the encumbrance is availing a business loan amounting to Rs. 1.25 crore. The value of the pledged shares on the date of the event was Rs. 2.50 crore, resulting in a security cover ratio of 2.0. The borrowed amount is intended for temporary business funding.

Prior to this transaction, Premier Fiscal Services Private Limited held 5,30,38,000 shares, representing 21.831% of the total share capital. Out of this, 1,00,00,000 shares were already encumbered. With the addition of the new pledge, the total encumbered shares held by the promoter now stand at 1,25,00,000, or 5.145% of the total share capital.

Gennex Laboratories reported a consolidated net profit of ₹2097.88 lacs for the financial year ended March 31, 2026, an increase from ₹1812.49 lacs in the prior year. Revenue from operations rose to ₹17274.09 lacs from ₹13790.30 lacs in FY25. The board approved the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, at a meeting held on May 30, 2026.

The company’s standalone net profit for FY26 was ₹1612.81 lacs, compared to ₹1403.68 lacs in the previous year. Standalone revenue from operations increased to ₹11985.67 lacs from ₹9457.79 lacs. The profit attributable to owners of the parent on a standalone basis was ₹1618.00 lacs.

Consolidated Financial Performance

The consolidated financial results for the year show growth across key metrics. Total income for FY26 was ₹18098.67 lacs, up from ₹14833.31 lacs in the previous year. Total expenses for the period amounted to ₹15714.90 lacs, compared to ₹12678.35 lacs in FY25.

Auditor's Observations

R Pugalia and Company, the statutory auditors, issued a qualified opinion in the audit report. The auditors noted that management had assured to obtain confirmations and reconciliations for balances of current assets, non-current assets, and liabilities, but the impact of this remains unascertained. Additionally, the company is in the process of installing Transaction Traceability Software in its accounting systems.

The Statement on Impact of Audit Qualifications confirmed that the impact of the qualification could not be ascertained. Management stated that the company had made efforts to obtain confirmations for advances, deposits, unsecured loans, trade receivables, and trade payables before signing the accounts. The company confirmed that the balances shown in the books are true and correct to the best of its knowledge.

Segment Reporting

The company operates in a single reportable segment: Bulk Drugs, Biotech Products, and Intermediates. Geographically, India remains the largest market, generating revenue of ₹8402.32 lacs in FY26, up from ₹6215.29 lacs in the previous year. Vietnam was the next largest market with revenue of ₹1346.70 lacs, followed by Colombia at ₹917.04 lacs.